(AMRX) Amneal Pharmaceuticals - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 3.962m USD | Total Return: 80.4% in 12m
Avg Turnover: 18.8M
EPS Trend: 57.9%
Qual. Beats: 5
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Amneal Pharmaceuticals, Inc. (AMRX) is a global biopharmaceutical firm focused on the development and distribution of generic, injectable, biosimilar, and specialty branded products. The company operates through three distinct segments: Affordable Medicines, which covers diverse dosage forms; Specialty, targeting central nervous system and endocrine disorders like Parkinson’s disease; and AvKARE, which serves government agencies and institutional customers.
The pharmaceutical sector often requires significant capital investment in Research and Development (R&D) to navigate complex regulatory approval processes and maintain a competitive pipeline. Amneal’s business model leverages a vertically integrated infrastructure across the United States, India, and Ireland to manage the production of high-barrier-to-entry generics and complex injectables.
Investors can evaluate the underlying fundamentals of this business model by reviewing the comprehensive data available on ValueRay. The company distributes its portfolio through a network of wholesalers, retail pharmacies, and managed care organizations to reach both private and public healthcare sectors.
- FDA approval and commercial launch of Crexont drives specialty segment revenue growth
- Expansion of biosimilar portfolio increases market share in high-margin injectable categories
- Government procurement contracts through AvKARE segment provide stable high-volume revenue streams
- Generic drug price erosion pressures margins across the affordable medicines business segment
- Research and development spending on complex generics impacts short-term operating cash flow
| Net Income: 122.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.16 > 1.0 |
| NWC/Revenue: 35.13% < 20% (prev 15.36%; Δ 19.77% < -1%) |
| CFO/TA 0.09 > 3% & CFO 303.9m > Net Income 122.4m |
| Net Debt (2.62b) to EBITDA (626.0m): 4.18 < 3 |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (328.9m) vs 12m ago 1.53% < -2% |
| Gross Margin: 38.66% > 18% (prev 0.37%; Δ 3.83k% > 0.5%) |
| Asset Turnover: 88.22% > 50% (prev 84.10%; Δ 4.12% > 0%) |
| Interest Coverage Ratio: 1.77 > 6 (EBITDA TTM 626.0m / Interest Expense TTM 237.5m) |
| A: 0.30 (Total Current Assets 1.80b - Total Current Liabilities 728.0m) / Total Assets 3.54b |
| B: -0.13 (Retained Earnings -472.7m / Total Assets 3.54b) |
| C: 0.12 (EBIT TTM 419.4m / Avg Total Assets 3.45b) |
| D: -0.17 (Book Value of Equity -581.7m / Total Liabilities 3.50b) |
| Altman-Z'' = 2.19 = BBB |
| DSRI: 1.05 (Receivables 902.7m/800.3m, Revenue 3.05b/2.83b) |
| GMI: 0.95 (GM 38.66% / 36.69%) |
| AQI: 0.84 (AQ_t 0.33 / AQ_t-1 0.40) |
| SGI: 1.08 (Revenue 3.05b / 2.83b) |
| TATA: -0.05 (NI 122.4m - CFO 303.9m) / TA 3.54b) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of May 30, 2026, the stock is trading at USD 13.17 with a total of 2,187,313 shares traded.
Over the past week, the price has changed by +6.04%,
over one month by +2.89%,
over three months by -4.63% and
over the past year by +80.41%.
Amneal Pharmaceuticals has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy AMRX.
- StrongBuy: 1
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.2 | 30.6% |
P/E Trailing = 33.5676
P/E Forward = 6.2972
P/S = 1.3009
P/B = 105.446
Revenue TTM = 3.05b USD
EBIT TTM = 419.4m USD
EBITDA TTM = 626.0m USD
Long Term Debt = 2.57b USD (from longTermDebt, last quarter)
Short Term Debt = 21.5m USD (from shortTermDebt, last quarter)
Debt = 2.81b USD (from shortLongTermDebtTotal, last quarter) + Leases 124.7m
Net Debt = 2.62b USD (calculated: Debt 2.81b - CCE 197.7m)
Enterprise Value = 6.58b USD (3.96b + Debt 2.81b - CCE 197.7m)
Interest Coverage Ratio = 1.77 (Ebit TTM 419.4m / Interest Expense TTM 237.5m)
EV/FCF = 32.05x (Enterprise Value 6.58b / FCF TTM 205.3m)
FCF Yield = 3.12% (FCF TTM 205.3m / Enterprise Value 6.58b)
FCF Margin = 6.74% (FCF TTM 205.3m / Revenue TTM 3.05b)
Net Margin = 4.02% (Net Income TTM 122.4m / Revenue TTM 3.05b)
Gross Margin = 38.66% ((Revenue TTM 3.05b - Cost of Revenue TTM 1.87b) / Revenue TTM)
Gross Margin QoQ = 44.31% (prev 36.50%)
Tobins Q-Ratio = 1.86 (Enterprise Value 6.58b / Total Assets 3.54b)
Interest Expense / Debt = 8.44% (Interest Expense 237.5m / Debt 2.81b)
Taxrate = 2.71% (2.18m / 80.2m)
NOPAT = 408.0m (EBIT 419.4m * (1 - 2.71%))
Current Ratio = 2.47 (Total Current Assets 1.80b / Total Current Liabilities 728.0m)
Debt / Equity = -61.97 (negative equity) (Debt 2.81b / totalStockholderEquity, last quarter -45.4m)
Debt / EBITDA = 4.18 (Net Debt 2.62b / EBITDA 626.0m)
Debt / FCF = 12.75 (Net Debt 2.62b / FCF TTM 205.3m)
Total Stockholder Equity = -84.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.54% (Net Income 122.4m / Total Assets 3.54b)
RoE = 31.52% (Net Income TTM 122.4m / Total Stockholder Equity 388.2m)
RoCE = 14.20% (EBIT 419.4m / Capital Employed (Equity 388.2m + L.T.Debt 2.57b))
RoIC = 14.92% (NOPAT 408.0m / Invested Capital 2.73b)
WACC = 8.77% (E(3.96b)/V(6.78b) * Re(9.16%) + D(2.81b)/V(6.78b) * Rd(8.44%) * (1-Tc(0.03)))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 14.26%
[DCF] Terminal Value 72.04% ; FCFF base≈216.8m ; Y1≈195.1m ; Y5≈166.0m
[DCF] Fair Price = N/A (negative equity: EV 2.48b - Net Debt 2.62b = -139.9m; debt exceeds intrinsic value)
EPS Correlation: 57.91 | EPS CAGR: 8.89% | SUE: 2.33 | # QB: 5
Revenue Correlation: 98.99 | Revenue CAGR: 11.13% | SUE: 0.24 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.23 | Chg30d=-0.83% | Revisions=+20% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.27 | Chg30d=-1.24% | Revisions=+33% | Analysts=6
EPS current Year (2026-12-31): EPS=0.99 | Chg30d=+0.08% | Revisions=+33% | GrowthEPS=+19.0% | GrowthRev=+2.7%
EPS next Year (2027-12-31): EPS=1.16 | Chg30d=-2.11% | Revisions=+0% | GrowthEPS=+17.1% | GrowthRev=+7.4%
[Analyst] Revisions Ratio: +33%